FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2923800831> ?p ?o ?g. }

• W2923800831 abstract "Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that inhibits PI3K/Akt and MAPK signaling pathways after HER2 receptor activation. The ExteNET study showed that neratinib significantly improved 5-year invasive disease-free survival (iDFS) in women who completed trastuzumab-based adjuvant therapy for early breast cancer (EBC). We assessed the prognostic and predictive significance of PIK3CA alterations in patients in ExteNET. Participants were women aged ≥ 18 years (≥ 20 years in Japan) with stage 1–3c (modified to stage 2–3c in February 2010) operable breast cancer, who had completed (neo)adjuvant chemotherapy plus trastuzumab ≤ 2 years before randomization, with no evidence of disease recurrence or metastatic disease at study entry. Patients were randomized to oral neratinib 240 mg/day or placebo for 1 year. Formalin-fixed, paraffin-embedded primary tumor specimens underwent polymerase chain reaction (PCR) PIK3CA testing for two hotspot mutations in exon 9, one hot-spot mutation in exon 20, and fluorescence in situ hybridization (FISH) analysis for PIK3CA amplification. The primary endpoint (iDFS) was tested with log-rank test and hazard ratios (HRs) estimated using Cox proportional-hazards models. Among the intent-to-treat population (n = 2840), tumor specimens were available for PCR testing (991 patients) and PIK3CA FISH (702 patients). Overall, 262 samples were PIK3CA altered: 201 were mutated (77%), 52 (20%) were amplified, and 9 (3%) were mutated and amplified. iDFS was non-significantly worse in placebo-treated patients with altered vs wild-type PIK3CA (HR 1.34; 95% CI 0.72–2.50; P = 0.357). Neratinib’s effect over placebo was significant in patients with PIK3CA-altered tumors (HR 0.41; 95% CI 0.17–0.90, P = 0.028) but not PIK3CA wild-type tumors (HR 0.72; 95% CI 0.36–1.41; P = 0.34). The interaction test was non-significant (P = 0.309). Although there was a greater absolute risk reduction associated with neratinib treatment of patients with PIK3CA-altered tumors in ExteNET, current data do not support PIK3CA alteration as a predictive biomarker of response to neratinib in HER2-positive EBC. ClinicalTrials.gov , NCT00878709 . Trial registered April 9, 2009." @default.
• W2923800831 created "2019-04-01" @default.
• W2923800831 creator A5001256203 @default.
• W2923800831 creator A5005769474 @default.
• W2923800831 creator A5006908391 @default.
• W2923800831 creator A5007997858 @default.
• W2923800831 creator A5008549101 @default.
• W2923800831 creator A5010004481 @default.
• W2923800831 creator A5011410319 @default.
• W2923800831 creator A5011877804 @default.
• W2923800831 creator A5012594351 @default.
• W2923800831 creator A5017550097 @default.
• W2923800831 creator A5026459010 @default.
• W2923800831 creator A5027877389 @default.
• W2923800831 creator A5030497065 @default.
• W2923800831 creator A5034630560 @default.
• W2923800831 creator A5035054317 @default.
• W2923800831 creator A5050048211 @default.
• W2923800831 creator A5050943019 @default.
• W2923800831 creator A5060930267 @default.
• W2923800831 creator A5068369453 @default.
• W2923800831 creator A5075481530 @default.
• W2923800831 creator A5079164469 @default.
• W2923800831 creator A5082292420 @default.
• W2923800831 creator A5083142899 @default.
• W2923800831 creator A5085474533 @default.
• W2923800831 creator A5086826368 @default.
• W2923800831 creator A5088946926 @default.
• W2923800831 date "2019-03-11" @default.
• W2923800831 modified "2023-10-18" @default.
• W2923800831 title "PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial" @default.
• W2923800831 cites W1574678914 @default.
• W2923800831 cites W1594020010 @default.
• W2923800831 cites W1597931794 @default.
• W2923800831 cites W1605218581 @default.
• W2923800831 cites W1963981090 @default.
• W2923800831 cites W1964808503 @default.
• W2923800831 cites W1967570571 @default.
• W2923800831 cites W1996778928 @default.
• W2923800831 cites W2029166421 @default.
• W2923800831 cites W2040935952 @default.
• W2923800831 cites W2044702943 @default.
• W2923800831 cites W2089605820 @default.
• W2923800831 cites W2096283457 @default.
• W2923800831 cites W2098775844 @default.
• W2923800831 cites W2104659222 @default.
• W2923800831 cites W2109529198 @default.
• W2923800831 cites W2112499354 @default.
• W2923800831 cites W2114149997 @default.
• W2923800831 cites W2114195503 @default.
• W2923800831 cites W2118419063 @default.
• W2923800831 cites W2131041693 @default.
• W2923800831 cites W2146384083 @default.
• W2923800831 cites W2149908785 @default.
• W2923800831 cites W2154246971 @default.
• W2923800831 cites W2160689007 @default.
• W2923800831 cites W2167359586 @default.
• W2923800831 cites W2170567505 @default.
• W2923800831 cites W2172265576 @default.
• W2923800831 cites W2264000214 @default.
• W2923800831 cites W2286693725 @default.
• W2923800831 cites W2352525452 @default.
• W2923800831 cites W2399215084 @default.
• W2923800831 cites W2471493685 @default.
• W2923800831 cites W2560367415 @default.
• W2923800831 cites W2587365770 @default.
• W2923800831 cites W2588881638 @default.
• W2923800831 cites W2613362156 @default.
• W2923800831 cites W2741991073 @default.
• W2923800831 cites W2768980003 @default.
• W2923800831 cites W2788279409 @default.
• W2923800831 doi "https://doi.org/10.1186/s13058-019-1115-2" @default.
• W2923800831 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6417207" @default.
• W2923800831 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30867034" @default.
• W2923800831 hasPublicationYear "2019" @default.
• W2923800831 type Work @default.
• W2923800831 sameAs 2923800831 @default.
• W2923800831 citedByCount "15" @default.
• W2923800831 countsByYear W29238008312019 @default.
• W2923800831 countsByYear W29238008312020 @default.
• W2923800831 countsByYear W29238008312021 @default.
• W2923800831 countsByYear W29238008312022 @default.
• W2923800831 countsByYear W29238008312023 @default.
• W2923800831 crossrefType "journal-article" @default.
• W2923800831 hasAuthorship W2923800831A5001256203 @default.
• W2923800831 hasAuthorship W2923800831A5005769474 @default.
• W2923800831 hasAuthorship W2923800831A5006908391 @default.
• W2923800831 hasAuthorship W2923800831A5007997858 @default.
• W2923800831 hasAuthorship W2923800831A5008549101 @default.
• W2923800831 hasAuthorship W2923800831A5010004481 @default.
• W2923800831 hasAuthorship W2923800831A5011410319 @default.
• W2923800831 hasAuthorship W2923800831A5011877804 @default.
• W2923800831 hasAuthorship W2923800831A5012594351 @default.
• W2923800831 hasAuthorship W2923800831A5017550097 @default.
• W2923800831 hasAuthorship W2923800831A5026459010 @default.
• W2923800831 hasAuthorship W2923800831A5027877389 @default.
• W2923800831 hasAuthorship W2923800831A5030497065 @default.
• W2923800831 hasAuthorship W2923800831A5034630560 @default.
• W2923800831 hasAuthorship W2923800831A5035054317 @default.
• W2923800831 hasAuthorship W2923800831A5050048211 @default.

• next